Letters to the Editor

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire, Lille, France;
Hopital Haut-Levêque, Centre Hospitalier Regional Universitaire de Bordeaux, Pessac, France;
Internal Medicine III, Ulm University, Ulm, Germany;
Hemato-Oncology Department, Hôpital Saint-Louis and Diderot University, Paris, France;
Hôpital de Pontchaillou, Rennes, France;
Universitätsmedizin Göttingen, Göttingen, Germany;
LMG PharmaTech, LLC., Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Eli Lilly and Company, Indianapolis, Indiana, USA;
Klinikum Nürnberg Nord, Nürnberg, Germany;
Universitätsmedizin Mainz, Mainz, Germany
Haematologica Early view May 7, 2020 https://doi.org/10.3324/haematol.2019.224535